Yuri An

TL;DR: 2F hDPC-hiPSCs have a robust capability for the generation of angiogenic and vasculogenic EPCs, representing a strategy for patient-specific EPC therapies and disease modeling, particularly for ischemic vascular diseases.

TL;DR: The VEGF–angiopoietin-1 chimera is a potent angiogenic factor that triggers a novel mode of V EGF receptor-2 activation, promoting less vessel leakiness, less tissue inflammation, and better perfusion in ischemic muscle than VEGf.

TL;DR: Treatment with PVE significantly enhanced cell proliferation, migration, and the capillary-like structure forming activity of cultured human umbilical vein endothelial cells (HUVECs) and indicated the need to identify the novel pro-angiogenic chemicals in the fractions of PVE.

TL;DR: Combined analysis of multiple parameters, especially onset time and modified T(max) which means the time from onset of ICG fluorescence to T( max), can be used as a reliable diagnostic tool for RP.

TL;DR: Although some blood flow parameters in the feet of DM patients with complications were close to normal blood flow, the vascular response of the macrovessels and microvessels to stimulation of the hands was significantly reduced, which indicates less reactivity in DM Patients with complications.